TD Cowen Initiates Coverage on TG Therapeutics (NASDAQ:TGTX)

Research analysts at TD Cowen began coverage on shares of TG Therapeutics (NASDAQ:TGTX - Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage set a "buy" rating and a $50.00 price target on the biopharmaceutical company's stock. TD Cowen's price target would suggest a potential upside of 94.48% from the stock's current price.

A number of other analysts have also weighed in on the company. B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. The Goldman Sachs Group upped their price objective on TG Therapeutics from $18.00 to $20.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $49.00 target price on shares of TG Therapeutics in a research note on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $34.43.

TG Therapeutics Stock Up 5.6 %

Shares of TGTX stock traded up $1.36 during mid-day trading on Tuesday, hitting $25.71. The stock had a trading volume of 4,104,119 shares, compared to its average volume of 3,621,523. TG Therapeutics has a 12-month low of $6.98 and a 12-month high of $26.41. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The firm's 50-day moving average is $23.44 and its two-hundred day moving average is $19.85. The firm has a market capitalization of $3.97 billion, a P/E ratio of 111.78 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. During the same period in the prior year, the firm earned ($0.34) earnings per share. The firm's revenue for the quarter was up 357.0% compared to the same quarter last year. On average, analysts predict that TG Therapeutics will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of TG Therapeutics

Large investors have recently bought and sold shares of the stock. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 485 shares during the period. Blue Trust Inc. increased its position in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 849 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics in the second quarter valued at approximately $35,000. ORG Wealth Partners LLC purchased a new position in shares of TG Therapeutics during the 3rd quarter valued at approximately $53,000. Finally, Values First Advisors Inc. acquired a new stake in TG Therapeutics in the 3rd quarter valued at $58,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.